An assessment of genetic factors influence on ibandronic acid effect in postmenopausal osteoporosis treatment can significantly bring us closer to the practical use of this results in prognostic genetics and personalized medicine. The aim was the study of associations between 283 A>G (BsmI, rs1544410) polymorphisms of vitamin D receptor gene (VDR) and ibandronic acid efficacy in postmenopausal osteoporosis treatment. 117 women with postmenopausal osteoporosis were examined through treatment dynamics. A 12-month therapy course included the use of ibandronic acid according to standard regimen. Evaluation of treatment effectiveness was carried out by changes (%) in bone mineral density (BMD) separately for each area by dual- energy X-ray absorptiometry. Real-time PCR was used to determine VDR gene rs1544410 polymorphism. It was found that for 12 months ibandronate use caused significant (p<0.001) BMD increase. BMD increase ranged from 2.71±0.53% in left femoral neck zone to 4.63±0.53% in the L1-L4 lumbar vertebrae. The treatment outcome did not depend (p>0.05) on age, height, weight, body mass index, and postmenopause duration. GG genotype of rs1544410 polymorphism was associated with lower BMD growth rate in L1-L4 lumbar vertebrae (p=0.036). Screening of women with postmenopausal osteoporosis for polymorphic variants of VDR gene (rs1544410) before antiresorptive therapy with ibandronic acid may be appropriate to predict the effect and individualize treatment and prophylactic measures. The obtained results can contribute to more complete understanding of osteoporosis pharmacogenetics
Vitamin D receptor gene, BsmI polymorphism, postmenopausal osteoporosis, treatment
1. Langdahl B. L. Overview of treatment approaches to osteoporosis. Br. J. Pharmacol. 2020. Epub ahead of print. doi:10.1111/bph.15024
2. Zaharov I. S., Kolpinskiy G. I., Shalamanova N. V., Kolesnik I. Yu., Lebedeva T. V., Titarenko O.V. Kompleksnyy podhod k terapii osteoporoza v postmenopauzal'nom periode v kontekste mezhdunarodnyh klinicheskih rekomendaciy. Consilium Medicum. 2019;21(6):50-53. doi:10.26442/20751753. 2019.6.190530
3. Marozik P., Alekna V., Rudenko E., Tamulaitiene M., Rudenka A., Mastaviciute A., Samokhovec V., Cernovas A., Kobets K., Mosse I. Bone metabolism genes variation and response to bisphosphonate 2020, tom 23, № 1 TAVRIChESKIY MEDIKO-BIOLOGIChESKIY VESTNIK treatment in women with postmenopausal osteoporosis. PLoS One. 2019;14(8): e0221511. doi:10.1371/journal. pone.0221511
4. Monahova A. I., Egorova E. V., Lyalina V. V., Storozhakov G. I. Farmakogenetika bisfosfonatov v lechenii postmenopauzal'nogo osteoporoza. Obzor literatury. Lechebnoe delo. 2013;3:53-8.
5. Lupez-Delgado L., Riancho-Zarrabeitia L., Riancho J.A. Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert. Opin. Drug. Metab. Toxicol. 2016;12(4):389-98.
6. Marini F., Brandi M.L. Pharmacogenetics of osteoporosis. Best. Pract. Res. Clin. Endocrinol. Metab. 2014;28(6):783-93.
7. Maylyan E. A. Vliyanie polimorfizma 283 A>G (BSMI) gena receptora vitamina D na razvitie osteoporoza u zhenschin v postmenopauze. Medicinskiy vestnik Yuga Rossii. 2016;4:32-8.
8. Maylyan E. A. Associacii polimorfizma 283 A>G (BSMI) gena receptora vitamina D s osteoporozom u zhenschin v zavisimosti ot dlitel'nosti postmenopauzy. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Medicina. Farmaciya. 2017;38(12):12-21.
9. Rudenko E. V., Rudenko E. V., Samohovec O. Yu., Kobec E. V., Marozik P. M. Associaciya polimorfnyh variantov gena receptora vitamina D s pokazatelyami mineral'noy plotnosti kostnoy tkani u zhenschin v menopauze. Izvestiya Nacional'noy akademii nauk Belarusi. Seriya medicinskih nauk. 2019;16(2):192-201. doi:10.29235/1814-6023-2019-16- 2-192-201
10. Krylov M. Yu., Nikitinskaya O. A., Samarkina E. Yu., Demin N. V., Toropcova N. V. Poisk geneticheskih markerov, opredelyayuschih effektivnost' terapii bisfosfonatami u rossiyskih zhenschin s postmenopauzal'nym osteoporozom: pilotnoe issledovanie. Nauchno-prakticheskaya revmatologiya. 2016;54(4):412-7. doi:10.14412/1995-4484-2016-412-417
11. Krylov M. Yu., Nikitinskaya O. A., Samarkina E. Yu., Toropcova N. V. Stronciya ranelat v lechenii postmenopauzal'nogo osteoporoza: effekt vliyaniya polimorfizmov genov receptora vitamina D i monocitarnogo hemoattraktantnogo belka 1 na mineral'nuyu plotnost' kosti (pilotnoe issledovanie). Nauchno-prakticheskaya revmatologiya. 2017;55(3):267-71. doi:10.14412/1995-4484-2017-267-271
12. Conti V., Russomanno G., Corbi G., Toro G., Simeon V., Filippelli W., Ferrara N., Grimaldi M., D’Argenio V., Maffulli N., Filippelli A. A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy. Int J Mol Sci. 2015;16(3):5452-66. doi: 10.3390/ ijms16035452
13. Lima C. A., Javorski N. R., Souza A. P., Barbosa A. D., Valenza A. P., Crovella S., Souza P. R., De Azevedo Silva J., Sandrin-Garcia P. Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women. Inflammopharmacology. 2017;25(2):191-201. doi:10.1007/s10787-017-0322-7
14. Mondockova V., Adamkovicova M., Lukacova M., Grosskopf B., Babosova R., Galbavy D., Martiniakova M., Omelka R. The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women. BMC Med Genet. 2018;19(1):174. doi: 10.1186/s12881- 018-0684-8
15. Wang J. Y., Zhou P. R., Liu Y., Xu X. J., Ma D. D., Xia W. B., Jiang Y., Wang O., Xing X. P., Li M. The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women. Pharmacogenomics. 2016;17(3):209-17. doi:10.2217/ pgs.15.167
16. Zheng H., Wang C., He J.W., Fu W.Z., Zhang Z.L. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia. Pharmacogenet. Genomics. 2016;26(1):12-9. doi:10.1097/FPC.0000000000000181
